Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Supporting the following funding levels in FY25 appropriations bills:
LHHS- $500 million for the Agency for Healthcare Research and Quality, $11.5 billion for the Centers for Disease Control and Prevention (inclusive of $5 million for the National Neurological Conditions Surveillance System), $20 million for the Lifespan Respite Care Program, Robust support for Medicare and Medicaid and protection of Medicaid's current financing structure, $51.3 billion for the National Institutes of Health, and at least $ 53.85 billion for the Indian Health Service.

DoD- $20 million for the MS Research Program and increased baseline funding of at least 5% plus inflation for the Congressionally Directed Medical Research Programs.

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), Natl Institutes of Health (NIH)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), Natl Institutes of Health (NIH), Indian Health Service, Agency for Healthcare Research & Quality (AHRQ)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

S.652 - Safe Step Act (Murkowski/Hassan), support passage
H.R. 830 - HELP Copays Act, support passage
S.935- Fair Accountability and Innovative Research Drug Pricing Act of 2023, support passage
H.R. 485, Protecting Health Care For All Patients Act, oppose passage as currently written
S.127, the Pharmacy Benefit Manager Transparency Act, support passage
Urged HELP and House Energy and Commerce Committee to hold roundtables and advance proposals that address workforce issues within the healthcare community.
S. 2333 - Pandemic and All-Hazards Preparedness and Response Act, support passage
H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023, oppose passage
H.R. 4421, Preparing for All Hazards and Pathogens Reauthorization Act, monitor legislation
H.R. 4420, Preparedness and Response Reauthorization Act, monitor legislation
Committee Draft -The Primary Care and Health Workforce Expansion Act, support passage
S. 1339, the Pharmacy Benefit Manager Reform Act, support passage
S.127, the PBM Transparency Act of 2023, support passage
S.113, The Prescription Pricing for the People Act of 2023, support passage
S.2052, Protect Patient Access to Pharmacies Act
H.R. 3561, the PATIENT Act of 2023, support passage
H.R. 3284, Providers and Payers Compete Act, support passage
H.R. 4507, Transparency in Coverage Act, support passage
H.R. 4508, Hidden Fee Disclosure Act, support passage
H.R. 2816, PBM Sunshine and Accountability Act, support passage
S.79- Interagency Patent Coordination and Improvement Act of 2023, support passage
S. 142- Preserve Access to Affordable Generics and Biosimilars Act, support passage
S.148- Stop STALLING Act, support passage
S.150- Affordable Prescriptions for Patients Act of 2023, support passage
S.775-Increasing Transparency in Generic Drug Applications Act, monitoring
S.1067-Ensuring Timely Access to Generics Act of 2023, support passage
S. 2780 Medication Affordability and Patent Integrity Ac
H.R. 4189, the CONNECT for Health Act, support passage
H.R. 1843, the Telehealth Expansion Act, support passage
H.R. 8018, the Alleviating Barriers for Caregivers Act, support passage
S. 3109, the Alleviating Barriers for Caregivers Act, support passage
H.R.6302, the Health Share Transparency Act of 2023

Joined together with coalition allies to offer recommendations for the 2026 Notice of Benefit and Payment Parameters (NBPP), as well as future rulemaking, to advance the goals of making healthcare accessible, adequate, and affordable.

Joined together with coalition allies to advocate to the federal government, including HHS and CMS, to ensure that any revision of the cost-sharing rule related to copay accumulator adjustment policies includes clear, commonsense protections guaranteeing that copayments made by or on behalf of an enrollee are counted as payments toward their annual cost-sharing contributions.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Support legislation that would: maintaining current Medicaid funding structure and make the enhanced advance premium tax credits permanent, support limiting the use of inadequate short-term limited duration and other non-ACA compliant plans, address affordability of health insurance out-of-pocket costs by shifting the APTC benchmark from silver plans to gold plans to decrease out of pocket exposure for patients, ensuring the actuarial value of plans accurately reflect the financial risk faced by most consumers enrolled in the plan, support and expand Medicaid coverage in states that have not yet expanded.

S.1967, Patients Before Middlemen Act, support passage
S.2973, Modernizing and Ensuring PBM Accountability Act, support passage (awaiting bill number)
S.2254, Medicare PBM Accountability Act, support passage

In June, the Society provided input on prototype Medicare Prescription Payment Plan documents released by the Centers for Medicare and Medicaid Services. The Societys comments focused on suggestions to improve these documents so that all Medicare beneficiaries will be able to understand how to access this program regardless of preferred language or disability status.

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Office of Administration

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Office of Administration

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

S.79 - Interagency Patent Coordination and Improvement Act of 2023, support passage
S.113, the Prescription Pricing for the People Act of 2023,support passage
S.142, the Preserve Access to Affordable Generics and Biosimilars Act, support passage
S.148, the Stop Stalling Act, support passage
S.150, the Affordable Prescriptions for Patients Act of 2023, support passage
H.R.1114- Long COVID Recovery Now Act
S.801/H.S. 1616 CARE for Long COVID Act, support passage
The Biosimilar Red Tape Elimination Act, monitor legislation

U.S. HOUSE OF REPRESENTATIVES, U.S. Senate, Natl Institutes of Health (NIH), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRA

16. Specific lobbying issues

Supported the Federal Aviation Administration (FAA) Reauthorization bill, HR 3935, the Securing Growth and Robust Leadership in American Aviation Act. This reauthorization bill contained several disability-related accessibility provisions the Society advocated for to improve safety and accessibility, including: new training requirements for assisting passengers with limited mobility and properly stowing assistive devices to prevent damage.

Submitted individual and signed onto coalition comments on the Federal Aviation Administration (FAA)s proposed rule on Ensuring Safe Accommodations for Air Travelers with Disabilities Using Wheelchairs. The proposed rule contains numerous provisions which look to remove barriers to air travel for people who have disabilities and asking for feedback on safe and dignified air travel.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Federal Aviation Administration (FAA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes